| Technology Overview NS-01 | ||
| Technology | Botanical Extract and Lead Compounds for the Treatments on Huntington's Disease | |
| Mechanism | Activation of A2A & A3 receptor which reduce Htt aggregation | |
| Indication | Huntington's disease | |
| Efficacy | In vitro | T1-11 inhibits adenosine uptake and thus increases the
adenosine level in CSF T1-11 inhibits iNOS induction & NO production in microglia cell line during LPS-induced inflammation. |
| In vivo | Oral intake of TE, T1-C & T1-11 improved body weight, rotarod performance, and survival. (transgenic R6/2 mice) | |
| Development Stage | TE (Extract) Preclinical Stage T1-C, T1-11 Pharmacophore-based lead optimization and synthesis |
|
| Intellectual Property | Patents pending, US patent field @2006/04/04, TW patent field @2006/06/02, CN patent field @2007/04/09 | |
| Collaboration Opportunity | Technology licensing, Co-development, Research collaboration | |